X4 Pharmaceuticals (XFOR) Equity Ratio (2017 - 2025)

X4 Pharmaceuticals has reported Equity Ratio for 9 years, with the latest figure at 0.64 in Q4 2025.

• For the quarter ending Q4 2025, Equity Ratio rose 324.06% year-over-year to 0.64; the trailing twelve-month figure through Dec 2025 stood at 0.64 (up 324.06% YoY), and the FY2025 full-year result was 0.64, up 324.06% from the prior year.
• Equity Ratio for Q4 2025 stood at 0.64, up from 0.38 in the prior quarter.
• The five-year high for Equity Ratio was 0.65 in Q1 2021, with the low at 0.01 in Q1 2024.
• Historically, Equity Ratio has averaged 0.4 across 5 years, with a median of 0.4 in 2023.
• Annual changes were most pronounced in 2024 — Equity Ratio sank 97.78% — and 2025, when it soared 1810.93%.
• X4 Pharmaceuticals' Equity Ratio stood at 0.55 in 2021, then decreased by 13.42% to 0.48 in 2022, then retreated by 27.09% to 0.35 in 2023, then tumbled by 56.41% to 0.15 in 2024, then surged by 324.06% to 0.64 in 2025.
• The last three Equity Ratio figures came in at 0.64 (Q4 2025), 0.38 (Q3 2025), and 0.04 (Q2 2025), per Business Quant data.